03:56 AM EDT, 10/23/2025 (MT Newswires) -- Viking Therapeutics ( VKTX ) reported late Wednesday a Q3 loss of $0.81 per diluted share, wider than the $0.22 loss a year earlier.

Analysts polled by FactSet expected a loss of $0.70.

The company reported no revenue for the quarter, as expected.

Viking Therapeutics ( VKTX ) had $715 million in cash, cash equivalents and short-term investments as of Sept. 30, it said.